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ABSTRACT
Background. We sought to determine the significance of
Ki-67, one of the tumor cell proliferation markers, as a
useful prognostic factor in early breast cancer.
Methods. A total of 1080 consecutive patients with stage I
or II breast cancer that underwent surgery between 1998
and 2003 were enrolled. Patients were categorized on the
basis of the 2007 St. Gallen consensus and Adjuvant!
Online. The expression of Ki-67 in the tumor was assayed
by immunohistochemistry (cutoff value, 10%).
Results. Univariate analysis determined that tumor size,
lymph node involvement, histologic grade, estrogen recep-
tor, progesterone receptor, bcl-2, and Ki-67 (C10%) were
statistically significant for both overall survival (OS) and
distant metastasis-free survival (DFS). Of these factors,
lymph node involvement and high Ki-67 expression were
identified as independent prognostic factors for OS and DFS
on the basis of multivariate analysis. The survivals of inter-
mediate- and high-risk groups according to 2007 St. Gallen
consensus were further separated by Ki-67 expression level
(5-year DFS rate = 91.9% vs. 86.3% for Ki-67 \ 10% and
C10%, respectively in intermediate-risk group (P = .01); 5-
year DFS rate = 82.5% vs. 61.4% for Ki-67 \ 10% and
C10%, respectively in high-risk group (P = .01)). The sur-
vivals of low- and high-risk groups according to Adjuvant!
Online were further separated by Ki-67 expression level (5-
year DFS rate = 97.8% vs. 89.5% for Ki-67 \ 10% and
C10%, respectively in low-risk group (P = .02); 5-year DFS
rate = 9.4% vs. 82.6% for Ki-67 \ 10% and C10% in high-
risk group (P = .005)).
Conclusions. Ki-67 is an independent prognostic factor
for DFS and OS in early breast cancer and can provide
additional prognostic information on the risk stratification
with the use of the 2007 St. Gallen consensus and Adju-
vant! Online.
Among patients with early breast cancer, approximately
20% to 50% of patients who received only curative surgery
will experience disease recurrence and die of systemic
disease. These patients have obtained statistically signifi-
cant improvements of disease-free survival and overall
survival with the extensive use of adjuvant systemic ther-
apies.1 For this reason, many patients with early breast
cancer have received systemic treatment.
The St. Gallen consensus is a currently available
guideline for adjuvant treatment of breast cancer patients
that divides breast cancer patients with early breast cancer
into three risk groups (low-risk group, intermediate-risk
group, and high-risk group) on the basis of clinicopatho-
logic factors such as tumor size, nodal status, tumor grade,
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hormone receptor, human epidermal growth factor recep-
tor-2 (HER-2) expression, and age at diagnosis.2 However,
this consensus is not satisfactory for selecting subsets of
patients who are more likely to benefit from adjuvant
chemotherapy and predicting prognosis of patients with
early breast cancer.3,4
Adjuvant! Online (http://www.adjuvantonline.com/) is
one of the tools to quantitatively estimate the prognosis of
patients with breast cancer and the benefit of adjuvant sys-
temic therapy. It is based on a 10-year observed survival for
women age 36 to 69 years with breast cancer between 1998
and 1992 recorded in the Surveillance, Epidemiology, and
End Results Program registry in the United States.5 Esti-
mates of the efficacy of the use of adjuvant tamoxifen and
chemotherapy were derived from the Early Breast Cancer
Trialists’ Collaborative Group. Although Adjuvant! Online
is a useful method to predict the prognosis of disease and
benefit of treatment, it needs more validation and modifica-
tion because it is too optimistic for subgroups enriched with
adverse prognostic factors, such as progesterone receptor
(PgR) negativity and HER-2 overexpression.6
To identify high-risk patients for disease recurrence,
many prognostic factors have been described over the last
few decades. Tumor size, nodal status, and histological
grade are known as prognostic factors of breast cancer and
are used for identifying patients who might benefit from
adjuvant chemotherapy.7 Among clinical variables, age at
diagnosis is a validated prognostic marker. Especially
patients younger than 35 years of age had shown unfa-
vorable prognosis.8 For the last few years, as attention on
the molecular features of tumors has been increased, sev-
eral biomarkers have been demonstrated as prognostic
factors. For example, hormone receptors have been used
for predicting prognosis and selecting therapeutic modali-
ties such as the administration of tamoxifen. Recently,
expression of HER-2, an oncogenetic transmembrane
growth factor receptor, has been demonstrated as a prog-
nostic surrogate and might be used to modify the previous
St. Gallen consensus and help select therapy such as
trastuzumab.9 Although many prognosticators have been
reported, the determination of more accurate and clinically
available markers remain a major challenge.10
Because rapid tumor proliferation is a critical feature for
tumor aggressiveness, proliferation markers have been
extensively evaluated as prognostic tools in breast can-
cer.11 Ki-67 is a cell proliferation-associated antigen that is
expressed in all stages of the cell cycle except G.0
12
Determination of the percentage of Ki-67 expression has
become a standard method to assess the proliferative
activity of tumor cells.13 Several investigations have
reported that Ki-67 overexpression is related to an unfa-
vorable outcome for breast cancer.14,15 In recent studies of
gene-expression profiling for breast cancer, Ki-67 has been
identified as one of the selected genes used to predict
disease recurrence.16 Despite the many articles published
that analyze the prognostic role of Ki-67 in early breast
cancer, it is still not considered to be an available prog-
nosticator in clinical practice.10,17–19
The purpose of the current study was to identify prog-
nostic factors in early breast cancer and to determine the
importance of Ki-67 as a prognostic factor in risk groups that
are based on the St. Gallen consensus and Adjuvant! Online.
MATERIALS AND METHODS
Patients
The study population consisted of 1080 consecutive
patients with a pathologic diagnosis of stage I or stage II
breast cancer based on the American Joint Committee on
Cancer cancer staging manual. Patients were enrolled
between January 1998 and December 2003 at the Depart-
ment of Surgery, Seoul National University College of
Medicine. Local therapies consisted of mastectomy or
breast-conserving surgery. Six hundred seventy patients
(62.0%) underwent mastectomy, and 410 patients (38.0%)
underwent breast-conserving surgery. Adjuvant radiother-
apy followed after breast-conserving surgery, and 799
patients (74.0%) received adjuvant chemotherapy. The
regimens were a combination of cyclophosphamide,
methotrexate, and 5-fluorouracil (CMF) or an anthracy-
cline-containing regimen. Adjuvant hormone therapy was
administered when estrogen receptor (ER) or PgR was
positive by immunohistochemistry (IHC). None of patients
was treated with trastuzumab as adjuvant therapy. Patients
diagnosed with pure in-situ carcinoma or who showed
distant metastasis at the time of diagnosis were excluded
from the analysis. Patients who underwent neoadjuvant
chemotherapy also were excluded.
IHC
The routinely formalin-fixed, paraffin-embedded tissue
blocks were sectioned at a 4-lm thickness and processed
for IHC. Paraffin was removed from tissue sections with
xylene. The sections were rehydrated with graded ethanol
and immersed in Tris-buffered saline. Representative sec-
tions were immunostained, and[10 randomly chosen high-
power fields were examined under an optical microscope.
The companies that supplied the primary antibodies and
the dilution factors used were as follows; ER (1DO5; Dako;
1:50), PgR (PgR636; Dako; 1:50), p53 (DO-7A; Dako;
1:1200), HER-2 (CB11; Novocastra Laboratories, New-
castle-Upon-Tyne, UK; 1:200), bcl-2 (124; Dako; 1:50),
and Ki-67 (MIB-1; Dako; 1:800). Biotinylated anti-mouse
antibody was used as a secondary antibody, and streptavidin
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horseradish peroxidase (Zymed Laboratories, San Fran-
cisco, CA) methods were used following the instructions
provided by the manufacturer. Finally, the sections were
counterstained in Mayer’s hematoxylin, dehydrated, and
cleared, and the sections were mounted for examination.
The slides were examined and scored by one patholo-
gist. A cutoff value of C10% of the positively stained
nuclei was used to define ER and PgR positivity. Only
cytoplasmic staining was scored as positive for bcl-2,
regardless of the intensity of the stained cells. Membranous
staining for HER-2 was scored as the following: 0, faint
incomplete staining in B10% of the cells; 1? , faint
incomplete staining in [10% of the cells; 2?, weak to
moderate complete staining in [10% of the cells; 3?,
strong complete staining in[10% of the cells. Cells stained
for Ki-67 and p53 were counted and expressed as a per-
centage. The percentage was determined by the number of
Ki-67-positive cells among the total number of total
counted tumor cells.
St. Gallen Consensus
Patients were divided into three groups in accordance
with the St. Gallen consensus published in 2007.20 The
tumor grade was determined according to the Scarff-
Bloom-Richardson classification modified by Elston and
Ellis.21 ER, PgR, and HER-2 expression was defined by
IHC. The low-risk group consisted of patients with node-
negative disease who had all of the following features:
tumor size B2 cm, tumor grade 1 or 2, expression of ER
and/or PgR, HER-2 neither overexpressed nor amplified,
and age C35 years. Patients with node-positive and ER and
PgR absent, or HER-2 gene overexpressed or amplified
were classified into the high-risk group. In this study,
patients with tumor grade 2 without another risk factor
were included in the low-risk group. Tumors with 3? in
IHC were defined as positive for HER-2 overexpression.
Adjuvant! Online
We calculated the 10-year survival probability of
patients by Adjuvant! software version 8.0 (http://www.
adjuvantonline.com/), which is based on the patient’s age,
tumor size and grade, tumor ER status, and nodal status.
Patients were divided into two subgroups (low and high) by
using two cutoffs that were decided by consensus of the
translational research established by the Breast Interna-
tional Group (TRANSBIG) consortium members (http://
www.breastinternationalgroup.org/). The low-risk group
was defined as patients with a 10-year survival probability
of at least 88% with positive expression of ER and of at
least 92% with negative expression of ER.
Statistical Methods
The study end points were distant metastasis-free sur-
vival (DFS) and overall survival (OS). The DFS period was
defined as the interval from the date of operation to the date
of the first observation of a distant metastasis or the last
follow-up date without evidence of distant metastasis. The
OS period was calculated from the date of operation to the
date of death or the last follow-up date when the patients
was alive. Survival rates were calculated by the Kaplan-
Meier method, and comparisons between groups were
made by the log rank test. For multivariate analysis, Cox
regression analysis was used. Statistical analysis was per-
formed by SPSS 13.0 for Windows (SPSS, Chicago, IL).
Ethics
This study protocol was reviewed and approved by the
Institutional Review Board of Seoul National University
Hospital; it complied with the recommendations of the
Declaration of Helsinki for biomedical research involving
human subjects.
RESULTS
Clinicopathological Characteristics of the Patients
One thousand eighty patients with stage I and II breast
cancer were enrolled onto the study. The median age at
diagnosis was 47 years (range, 21–83 years). The median
follow-up duration was 43.9 months (range, 13–
117 months). One hundred ten patients (10.2%) experienced
disease recurrence, and 37 patients (3.4%) died. The clini-
copathological features of the enrolled patients are listed in
Table 1.
Univariate and Multivariate Analysis
Table 1 shows the result of univariate analysis for DFS.
Statistically significant prognostic factors for DFS were age
at diagnosis, tumor size, lymph node involvement, histo-
logic grade, adjuvant chemotherapy, ER, PgR, HER-2, bcl-
2, and Ki-67. However, menopausal status, nuclear grade,
p53, and adjuvant hormone therapy were not statistically
significant. OS was related to tumor size, lymph node
involvement, histologic grade, ER, PgR, p53, bcl-2, and Ki-
67. However, age at diagnosis, menopausal status, nuclear
grade, and HER-2 were not statistically significant factors.
Multivariate analysis was performed for the DFS and
OS by using statistically significant variables as determined
by univariate analysis. Age at diagnosis (hazard ratio [HR]
1.81; 95% confidence interval [95% CI], 1.02–3.19), lymph
node involvement (HR 2.60; 95% CI, 1.71–3.92), and Ki-
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67 overexpression (HR 1.84; 95% CI, 1.17–2.90) were
identified as independent factors significantly associated
with recurrence (Table 2). Lymph node involvement (HR
3.35; 95% CI, 1.70–6.60) and Ki-67 overexpression (HR
2.49; 95% CI, 1.19-5.20) correlated with unfavorable OS
(Table 3).
Association Between Ki-67 Expression and Other
Prognostic Markers
The association between Ki-67 expression and other
prognostic markers were assessed for the patients with
early breast cancer (Table 4). Ki-67 expression was found
to be correlated with tumor size, tumor grade, p53
expression, and HER-2 expression (P \ .001). Expression
of ER, PgR, and bcl-2 expression were inversely correlated
with Ki-67 expression (P \ .001). However, there was no
relation between Ki-67 and nodal status. The patients with
Ki-67 overexpression were treated with chemotherapy
much more than the patients without Ki-67 overexpression
(P \ .001).
DFS According to Ki-67 Expression and Hormone
Receptor Status
Considering the inverse correlation of Ki-67 and hor-
mone receptor, hormone receptor-positive and -negative
subgroups were analyzed separately for DFS rate according
to Ki-67 expression. In tumors with hormone receptor, the
5-year DFS rate was 94.8% with Ki-67 \ 10% tumor and
86.0% with Ki-67 C 10% tumor (P = .004, Fig. 1a).
Patients without hormone receptor expression showed a
statistically significant difference of DFS with Ki-67
expression (5-year DFS rate, 89.4% for Ki-67 \ 10%
tumor vs. 84.7% for Ki-67 C 10% tumor, P = .03,
Fig. 1b).
TABLE 1 Characteristics of
patients and univariate analysis
of possible prognostic factors
for 5-year distant metastasis-
free survival (DFS) and overall
survival (OS)
pN pathological nodal stage, NG
nuclear grade, HG histological
grade, ER estrogen receptor,
PgR progesterone receptor,
HER-2 human epidermal
growth factor receptor-2, HT
hormone therapy
Characteristic Group n (%) DFS (%) P value OS (%) P value
Age (y) \35 94 (8.7) 82.9 .01 97.8 .52
C35 986 (91.3) 90.5 96.5
Menopause Premenopause 647 (59.9) 89.8 .8 97.2 .12
Postmenopause 433 (40.1) 89.4 95.6
Size (cm) B2 518 (48.0) 92.9 .003 98.3 .005
[2 562 (52.0) 87 95
pN 0 748 (69.3) 92.7 \.001 98 \.001
1 332 (30.7) 83.4 93.4
NG 1,2 671 (62.1) 91.1 .14 97.5 .06
3 381 (35.3) 87.2 94.7
Unknown 28 (2.6)
HG 1,2 586 (54.3) 91.5 .02 97.8 .005
3 392 (36.3) 85.5 93.9
Unknown 102 (9.4)
ER Positive 576 (53.3) 92.7 .02 98.8 \.001
Negative 504 (46.7) 86.5 94.1
PgR Positive 404 (37.4) 94.1 .007 99 .004
Negative 676 (62.6) 87.3 95.1
p53 \50% 818 (75.7) 90.1 .52 97.2 .05
C50% 247 (22.9) 88.3 94.3
HER-2 Positive (3?) 199 (18.4) 86.9 .05 95.5 .18
Negative (0, 1?, 2?) 822 (76.1) 91.2 97.2
Unknown 59 (5.5)
bcl-2 Positive 705 (65.3) 91.8 .02 98 .003
Negative 359 (33.2) 85.5 93.6
Ki-67 \10% 732 (67.8) 92.6 \.001 98.2 \.001
C10% 324 (30.0) 83 92.9
Chemotherapy Done 799 (74.0) 86.9 \.001 95.8 .09
Not done 281 (36.0) 98.2 98.6
HT Done 549 (50.8) 92.4 .07 98.7 .002
Not done 367 (34.0) 88.3 95.4
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DFS According to Ki-67 Expression and Chemotherapy
Regimens
Considering the variability of chemotherapy regimens,
survivals by Ki-67 expression were analyzed separately
according to chemotherapy regimens. Two hundred eighty-
one patients (26.0%) did not receive chemotherapy, 548
patients (50.7%) were treated with CMF, and 251 patients
(23.3%) were treated with anthracycline-containing che-
motherapy. In patients who did not receive chemotherapy,
the survival was worse when Ki-67 expression was high in
the tumor, although it is nonsignificant (5-year DFS rate,
98.7% for Ki-67 \ 10% tumor vs. 95.7% for Ki-67 C 10%
tumor, P = .21, Fig. 2a). Patients treated with CMF showed
a significant difference of DFS according to Ki-67 expres-
sion (5-year DFS rate, 90.4% for Ki-67 \ 10% tumor vs.
83.2% for Ki-67 C 10% tumor, P = .01, Fig. 2b). In sub-
group treated with anthracycline- containing chemotherapy,
there was a significant difference of DFS according to Ki-67
expression (5-year DFS rate, 90.2% for Ki-67 \ 10% tumor
vs. 78.8% for Ki-67 C 10% tumor, P = .003, Fig. 2c).
DFS of Risk Groups Based on the St. Gallen
Classification and Adjuvant! Online
Patients were divided into three risk groups (low,
intermediate, and high) according to the 2007 St. Gallen
consensus. We were able to classify 1066 patients (98.7%).
A total of 196 patients (18.4%) were classified as low risk,
786 patients (73.7%) as intermediate risk, and 84 patients
(7.9%) as high risk. When the DFS rates of subgroups were
compared, high-risk patients showed unfavorable prognosis
compared with intermediate- and low-risk patients (5-year
DFS, 71.4% for high-risk group vs. 90.1% for intermedi-
ate-risk group vs. 97.5% for low-risk group, P \ .001).
On the basis of Adjuvant! Online, we found the median
10-year survival probability of enrolled patients was 80%
(range, 35%-99%). Two hundred forty-eight patients
(23.0%) were included in the low-risk group and 832
patients (77.0%) in the high-risk group. There was a sta-
tistically significant difference in DFS between the two risk
groups (5-year DFS, 87.6% for high-risk group vs. 97.2%
for low-risk group, P = .001).
Comparison of DFS According to Ki-67 Expression
in the St. Gallen Classification and Adjuvant! Online
We reclassified three risk groups of the St. Gallen
consensus according to Ki-67 expression and analyzed the
DFS rate of each subgroup. In the low-risk group, there was
no difference of DFS rate with or without Ki-67 overex-
pression (Fig. 3a). The 5-year DFS rate was 91.9% with
Ki-67 \ 10% tumor and 86.3% with Ki-67 C 10% tumor
among intermediate-risk patients (P = .01, Fig. 3b). In
high-risk patients, there was significant difference of DFS
by Ki-67 expression (5-year DFS rate, 82.5% for Ki-
67 \ 10% tumor vs. 61.4% for Ki-67 C 10% tumor,
P = .01, Fig. 3c).
For two subgroups of Adjuvant! Online, we compared
the DFS rate according to Ki-67 expression. In both sub-
groups, there were statistically significant differences of
DFS rates with or without Ki-67 overexpression. The 5-
year DFS rate was 97.8% with Ki-67 \ 10% tumor and
89.5% with Ki-67 C 10% tumor in low-risk patients
(P = .02, Fig. 4a). In the high-risk subgroup, DFS rates by
Ki-67 expression were significantly different (5-year DFS
rate, 90.4% for Ki-67 \ 10% tumor vs. 82.6% for Ki-
67 C 10% tumor, P = .005, Fig. 4b).
DISCUSSION
The current study was designed to evaluate the impor-
tance of Ki-67 as a prognostic factor in early breast cancer.
We have demonstrated that Ki-67 is an independent
prognostic marker for DFS and OS of early breast cancer.
TABLE 2 Multivariate analysis of prognostic factors for the 5-year
disease-free survival rate
Characteristic HR 95% CI P value
Age at diagnosis (\35 y) 1.81 (1.02, 3.19) .042
Tumor size ([2 cm) 1.35 (.86, 2.11) .194
Lymph node involvement (positive) 2.60 (1.71, 3.92) \.001
HG (III) 1.07 (.66, 1.73) .788
ER (negative) .85 (.49, 1.47) .562
PgR (negative) 1.34 (.75, 2.40) .320
HER-2 (positive) 1.33 (.83, 2.13) .239
bcl-2 (negative) 1.39 (.84, 2.33) .200
Ki-67 (C10%) 1.84 (1.17, 2.90) .008
HR hazard ratio, 95% CI 95% confidence interval, HG histological
grade, ER estrogen receptor, PgR progesterone receptor, HER-2
human epidermal growth factor receptor-2
TABLE 3 Multivariate analysis of prognostic factors for 5-year
overall survival rate
Characteristic HR 95% CI P value
Tumor size ([2 cm) 1.95 (.89, 4.25) .092
Lymph node involvement (positive) 3.35 (1.70, 6.60) \.001
HG (III) 1.01 (.45, 2.25) .979
ER (negative) 2.06 (.71, 5.98) .182
PgR (negative) 1.57 (.44, 5.63) .492
p53 (C50%) 1.13 (.54, 2.37) .742
bcl-2 (negative) 1.28 (.59, 2.76) .536
Ki-67 (C10%) 2.49 (1.19, 5.20) .015
HR hazard ratio, 95% CI 95% confidence interval, HG histological
grade, ER estrogen receptor, PgR progesterone receptor
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The adverse effect of Ki-67 overexpression for both DFS
and OS was observed in the subgroups lymph node-nega-
tive and lymph node-positive patients as well as in the
overall population. In addition, analysis that used a com-
bination of Ki-67 status and St. Gallen consensus data
confirmed that Ki-67 expression had prognostic power in
the intermediate-risk and high-risk groups.
Several studies have evaluated the correlation between
Ki-67 expression and clinical outcome (DFS and/or
OS).11,18,22–26 Although the findings are controversial,
many studies have reported the independence of Ki-67
expression as a prognostic marker. In a meta-analysis of
Ki-67 in early breast cancer, Ki-67 overexpression resulted
in unfavorable survival in lymph node-negative and lymph
TABLE 4 Association
between Ki-67 expression and
other clinicopathologic factors
pN pathological nodal stage, HG




receptor-2, HT hormone therapy
Characteristic Group Ki-67 \ 10%, n (%) Ki-67 C 10%, n (%) P value
Age (y) \35 52 (7.1) 41 (12.6) .005
C35 680 (92.9) 283 (87.4)
Size (cm) B2 389 (53.1) 119 (36.7) \.001
[2 343 (46.9) 205 (63.3)
pN 0 508 (69.4) 223 (68.8) .89
1 224 (30.6) 101 (31.2)
HG 1,2 484 (73.8) 92 (30.2) \.001
3 172 (26.2) 213 (69.8)
ER Positive 462 (63.1) 102 (31.5) \.001
Negative 270 (36.9) 222 (68.5)
PgR Positive 337 (46.0) 59 (18.2) \.001
Negative 395 (54.0) 265 (81.8)
p53 \50% 621 (84.8) 189 (58.3) \.001
C50% 111 (15.2) 135 (41.7)
HER-2 Positive 109 (15.7) 88 (28.5) \.001
Negative 584 (84.3) 221 (71.5)
bcl-2 Positive 534 (72.9) 165 (51.1) \.001
Negative 198 (27.1) 158 (48.9)
Operation Conservation 459 (62.7) 197 (60.8) .58
Mastectomy 273 (37.3) 127 (39.2)
Chemotherapy Done 503 (68.7) 277 (85.5) \.001
Not done 229 (31.3) 47 (14.5)
HT Done 439 (69.4) 103 (38.3) \.001
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FIG. 1 Survival curves according to Ki-67 expression in hormone receptor-positive (a) and hormone receptor-negative (b) patients
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node-positive patients.17 This recent study showed the
same result in a subgroup analysis for nodal status. In a
study of protein expression profiling that used IHC with a
tissue microarray, Jacquemier et al. delineated protein
clusters associated with ER and with tumor proliferation,
and the investigators identified a set of 21 proteins whose
combined expression was statistically significantly corre-
lated with DFS.27 In multivariate analysis, the 21-protein
signature, tumor size, nodal status, and Ki-67 expression









Ki-67<10%, n = 229,
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FIG. 2 Survival curves according to Ki-67 expression and
chemotherapy. (a) No chemotherapy. (b) CMF. (c) Anthracycline-
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FIG. 3 Survival curves of subgroups according to Ki-67 in
risk groups of the St. Gallen consensus. (a) Low-risk group.
(b) Intermediate-risk group. (c) High-risk group
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Genomic studies have also demonstrated that Ki-67
expression affects the prognosis of breast cancer. Paik et al.
quantified the likelihood of distant metastases in patients
with lymph node-negative breast cancer by using a gene-
expression assay and an algorithm for calculation recurrence
scores.16 A panel of 21 genes included the estrogen group,
the proliferation group, and the HER-2 group. Ki-67 was a
representative gene of the proliferation group. In a 76-gene
signature of the study by Wang et al. and 70-gene profile by
van de Vijver et al., genes that were involved in cell prolif-
eration influenced distant metastasis of breast cancer.28,29
However, these gene assays are difficult to apply in the
clinical setting because of its high cost and its requirement
for fresh tissue. Therefore, Ki-67 expression determination
by immunoassay could be considered a convenient method
to evaluate tumor proliferation in clinical practice, and sub-
sequently for treatment decisions and prognosis prediction.
Because tumor proliferation is a central cause of disease
recurrence and distant metastases, many researchers have
sought a way to determine the proliferative rate in neo-
plasms. Previously established methods include the use of
the thymidine-labeling index, bromodeoxyuridine incorpo-
ration, and S-phase fraction measurement.30–32 However,
the use of antibodies to Ki-67 is known to be the most
reliable and simplest method to assess tumor proliferation.
In particular, the monoclonal antibody MIB-1, which has
been widely used in clinical practice and in this study, is
superior to other antibodies because it is readily detectable
in a paraffin-embedded section and provides good correla-
tion of the Ki-67 expression level in frozen sections.33
The recommendation for the cutoff of the level of Ki-67
expression affecting prognosis is controversial. Previous
investigations about Ki-67 expression and survival have
used 5%, 10%, 20%, 25%, or a median value as a cutoff
value.22–26,34,35 In this study, we calculated survival for
different cutoff values of Ki-67 expression (5%, 10%, 20%,
25%, and 50%) and concluded that 10% as cutoff provided
the best prognosis-prediction results. In a study about the
clinical implication of the Ki-67 cutoff value, the choice of
Ki-67 cutoff may depend on the clinical objective.36 If Ki-
67 expression is used to exclude patients with slowly
proliferating tumors from chemotherapy protocols, a cutoff
of 10% will help to avoid overtreatment. If Ki-67 expres-
sion is used to identify tumors that are sensitive to
chemotherapy, it seems preferable to set the cutoff at 25%.
For this reason, when we selected high-risk subsets of
patients for adjuvant chemotherapy, it was reasonable to
select 10% as a cutoff value in this study.
There were some explanations for the prognostic role of
Ki-67 expression in breast cancer. Some investigators have
reported an association between Ki-67 expression and other
prognostic variables, e.g., tumor grade, nodal status, tumor
size, age at diagnosis, hormone receptor status, and epi-
dermal growth factor receptor expression.19,37,38 This study
demonstrated that Ki-67 expression was related with tumor
size, tumor grade, and p53 expression, and had an inverse
association with favorable prognostic markers such as
hormone receptor and bcl-2 expression. Therefore, it was
necessary to adjust the other prognostic variables to eval-
uate the independent effect of Ki-67 expression. This
current study confirmed that Ki-67 expression was an
independent prognostic marker by multivariate analysis
when other associated factors were used as covariates.
The St. Gallen consensus, one of several currently
available criteria for adjuvant chemotherapy in breast
cancer, could reflect the prognosis of breast cancer in this
study. The survival comparison of the three risk groups
showed a statistically significant difference. However, the
St. Gallen consensus has several key problems. These
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FIG. 4 Survival curves according to Ki-67 expression in the risk groups of Adjuvant! Online. (a) Low-risk group. (b) High-risk group
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clinical practice.3,39,40 One problem is that the number of
patients in the low-risk group is too small. In this study,
only 196 patients (18.4%) were classified in the low-risk
group. In studies of the application of the St. Gallen con-
sensus for lymph node-negative patients, only 10% of
patients were classified as low risk.3,9 Because grade 2
tumors were included in the low-risk group in this study,
the percentage of the low-risk group was larger than when
only grade 1 tumors were included in low-risk group. If the
St. Gallen consensus is applied more strictly, only a few
patients could avoid adjuvant chemotherapy. The other
defect of the St. Gallen consensus is that the spectrum of
the intermediate-risk group was too broad. Seven hundred
eighty-six patients (73.7%) were classified as intermediate
risk. However, the prognoses of patients in this group were
heterogeneous. For example, the prognosis of patients with
Ki-67 \ 10% in the intermediate-risk group was not dif-
ferent with that of patients with Ki-67 C 10% in the low-
risk group (5-year DFS rate 91.9% vs. 93.3%).
Adjuvant! Online could provide estimates of survival
probability with and without adjuvant systemic therapy.
Several studies have validated the use of this software and
have used it for validation of other prediction models.6,41
However, Adjuvant! Online has a limitation because it does
not reflect other biomarkers such as PgR, HER-2, and Ki-67.
It should be modified by consideration of the prognostic
effects of these markers. Although Adjuvant! Online could
provide continuous values for survival probability and
treatment benefit, clinical decision assumes a dichotomiza-
tion into low- and high-risk groups. This study used two
cutoffs, 88% for ER-positive tumors and 92% for ER-neg-
ative tumors, that were decided by consensus among the
TRANSBIG consortium members (http://www.breast
internationalgroup.org/). However, Buyse et al. showed
poor sensitivity of Adjuvant! Online and improved it by
using other prediction models such as the 70-gene signature.6
Although this current study was a retrospective one with
a heterogeneous population for adjuvant treatment and
short-term median follow-up periods, it showed that Ki-67
has prognostic power regardless of chemotherapy regimens
(Fig. 2). To our knowledge, it is the first study to assess the
prognostic value of Ki-67 expression combined with the St.
Gallen consensus and Adjuvant! Online in early breast
cancer.
This study demonstrated that Ki-67 was an independent
prognostic factor in early breast cancer and could provide
additional prognostic information on the risk stratification
with the use of the 2007 St. Gallen consensus and Adju-
vant! Online.
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